A science advisory from the American Heart Association recommended that prescription n-3 fatty acids (eicosapentaenoic acid [EPA]+docosahexaenoic acid [DHA] or EPA-only) at a dose of 4 g/d (>3 g/d total EPA+DHA) are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid-lowering agents (https://www.ahajournals.org/). AstraZeneca announced that compared to placebo, dapagliflozin (a SGLT2 inhibitor) significantly reduced cardiovascular death or the worsening of heart failure (HF, defined as hospitalization or an urgent HF visit) in patients with and without type 2 diabetes with reduced ejection fraction on standard of care treatment (https://www.astrazeneca-us.com/). Data from a US community‐based cohort of 12 168 middle‐aged adults suggest that diets higher in plant foods and lower in animal foods were associated with a lower risk of cardiovascular morbidity and mortality in a general population (https://www.ahajournals.org/).
A secondary MRI analysis of the US POINTER randomized clinical trial found that a structured…
Dementia risk factors vary substantially across countries, but they frequently cluster together in similar patterns…
A systematic review and network meta-analysis of 262 randomized trials involving 99,791 participants found that…
Approximately 21% of patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events…
A Danish randomized crossover trial found that a single session of high-intensity interval exercise (HIIE)…
Baseline use of proton pump inhibitors (PPIs) and, to a lesser extent, antibiotics was associated…
This website uses cookies.